Anticoagulation choices in non valvular AF
NICE Atrial Fibrillation Guidelines NG196 April 2021

Patient confirmed to have non valvular atrial fibrillation on ECG recording. All forms of atrial fibrillation (paroxysmal, persistent, long term and permanent) require stroke risk assessment.

Undertake a CHA₂DS₂-VASc score
Score ≥1 for men or ≥2 for women

No

No thromboprophylaxis required. Do not give aspirin or other antiplatelet agents again unless indicated for other medical conditions.

Yes

Anticoagulation declined

Discuss with patient the risk of stroke, options for anticoagulation and bleeding risk (review ORBIT score). Consider:
• The patient’s clinical features and their individual preference (see patient decision aid )
• First line treatment is direct oral anticoagulant (DOAC)
• If DOAC contraindicated can the patient take warfarin (any previous allergic response or adverse effects)?
  o Does the patient have adequate venous access or near patient testing device
  o Can the individual manage medications without a compliance aid?

DOAC indicated

Treatment is direct oral anticoagulant (DOAC)
• Apixaban
• Dabigatran
• Edoxaban
• Rivaroxaban

There are four agents licensed:
Dose adjustments are required for age; renal function and body mass (refer to SPC/BNF).

Renal function, FBC and bleeding risk should be checked at least every 12 months. Review compliance including the number of prescriptions issued.

These medications currently cannot be monitored. Dabigatran has a licensed antidote. Apixaban and Rivaroxaban can be reversed as per TA697. Dabigitran cannot be used in standard compliance aids

DOAC contraindicated

Initiate warfarin therapy under the direction of an anticoagulation clinic / GP with a target INR of 2.0 – 3.0

Reassess anticoagulation for patients with poor anticoagulation control shown by any of the following over a six month period:
• 2 INRs over 5.0; or 1 value over 8.0
• 2 INRs less than 1.5
• Time in therapeutic range (TTR) less than 65%

GP to discuss with patient reasons for poor results:
- Cognitive function
- Adherence
- Illness
- Interacting medications
- Lifestyle factors including diet and alcohol consumption.

COULD INR BE IMPROVED?

Yes

Continue warfarin & check INR control. Annual reassessment by the GP of FBC, U&Es, LFTs and bleeding risk

No

Anticoagulation declined
Updated recommendations:

- Do not offer aspirin monotherapy solely for stroke prevention to people with AF. Use the CHA2DS2-VASc stroke risk score & offer anticoagulation to people with score of Score ≥1 for men or ≥2 for women taking into account the bleeding risk using the ORBIT score.

- Patients should be offered a choice of DOAC anticoagulants (apixaban, rivaroxaban dabigatran, edoxaban) as first line therapy as per NICE; treatment should be based on their clinical features and preferences. If patient declines DOAC or in contraindicated to DOAC a warfarin can be offered. Anticoagulation Patient decision aid, adapted from Vale of York CCG document, may be used to assist with this process.

- For patients already on warfarin and who are stable, continue with their current medication and discuss the option of switching treatment to DOAC at their next routine appointment, taking into account the person's time in therapeutic range.

- For patients on warfarin assess INR control at each visit. Reassess anticoagulation for a person with poor anticoagulation control shown by the following:
  - 2 INR values over 5.0 or 1 INR value higher than 8 within the past 6 months
  - 2 INR values less than 1.5 within the past 6 months
  - Time in therapeutic range (TTR) less than 65% within the past 6 months excluding measurements taken during the first six weeks.

- When reassessing anticoagulation take into account and address the following factors:
  - Cognitive function
  - Adherence to prescribed therapy
  - Illness
  - Interacting drug therapy
  - Lifestyle factors including diet & alcohol consumption

- For people who are taking an anticoagulant, review the need for anticoagulation and the quality of anticoagulation at least annually, or more frequently if clinically relevant events occur affecting anticoagulation or bleeding risk.

- For people who are not taking an anticoagulant because of bleeding risk or other factors, review stroke and bleeding risks annually, and ensure that all reviews and decisions are documented.

- Do not withhold anticoagulation solely because of a person's age or their risk of falls.

<table>
<thead>
<tr>
<th>CHA2DS2-VASc score</th>
<th>ORBIT score</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHF / LVEF &lt; 40%</td>
<td>Males with haemoglobin &lt;130 g/L or hematocrit &lt;40%. +2 or</td>
</tr>
<tr>
<td>History of Hypertension</td>
<td>Females with haemoglobin &lt;120 g/L or hematocrit &lt;36%. +2</td>
</tr>
<tr>
<td>Age ≥75</td>
<td>History of bleeding +2</td>
</tr>
<tr>
<td>Age = 64 – 74 years</td>
<td>Age ≥ 74 years +1</td>
</tr>
<tr>
<td>Diabetes</td>
<td>eGFR &lt; 60 mL/min/1.73m2 +1</td>
</tr>
<tr>
<td>History of Stroke / TIA /</td>
<td>Treated with antiplatelets +1</td>
</tr>
<tr>
<td>Thromboembolism</td>
<td></td>
</tr>
<tr>
<td>History of vascular disease</td>
<td></td>
</tr>
<tr>
<td>Gender = female</td>
<td></td>
</tr>
</tbody>
</table>